{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:58:52Z","timestamp":1787317132183,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Insulin-sensitizing medications were originally used in psychiatric practice to treat weight gain and other metabolic side effects that accompany the use of mood stabilizers, antipsychotics, and some antidepressants. However, in recent studies these medications have been shown to cause improvement in depressive symptoms, creating a potential new indication outside of metabolic regulation. However, it is still unclear whether the antidepressant properties of these medications are associated with improvements in metabolic markers. We performed a systematic search of the literature following PRISMA guidelines of studies investigating antidepressant effects of insulin-sensitizing medications. We specifically focused on whether any improvements in depressive symptoms were connected to the improvement of metabolic dysfunction. Majority of the studies included in this review reported significant improvement in depressive symptoms following treatment with insulin-sensitizing medications. Nine out of the fifteen included studies assessed for a correlation between improvement in symptoms and changes in metabolic markers and only two of the nine studies found such association, with effect sizes ranging from R\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.26\u20130.38. The metabolic variables, which correlated with improvements in depressive symptoms included oral glucose tolerance test, fasting plasma glucose and glycosylated hemoglobin following treatment with pioglitazone or metformin. The use of insulin-sensitizing medications has a clear positive impact on depressive symptoms. However, it seems that the symptom improvement may be unrelated to improvement in metabolic markers or weight. It is unclear which additional mechanisms play a role in the observed clinical improvement. Some alternative options include inflammatory, neuroinflammatory changes, improvements in cognitive functioning or brain structure. Future studies of insulin-sensitizing medications should measure metabolic markers and study the links between changes in metabolic markers and changes in depression. Additionally, it is important to use novel outcomes in these studies, such as changes in cognitive functioning and to investigate not only acute, but also prophylactic treatment effects.\n                  <\/jats:p>","DOI":"10.1038\/s41398-022-02234-z","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T12:13:22Z","timestamp":1667909602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Are the antidepressant effects of insulin-sensitizing medications related to improvements in metabolic markers?"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6047-0766","authenticated-orcid":false,"given":"Temi","family":"Toba-Oluboka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00fdna","family":"Vochoskov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-8458","authenticated-orcid":false,"given":"Tomas","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"2234_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","volume":"14","author":"D Vancampfort","year":"2015","unstructured":"Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry J World Psychiatr Assoc WPA. 2015;14:339\u201347. https:\/\/doi.org\/10.1002\/wps.20252.","journal-title":"World Psychiatry J World Psychiatr Assoc WPA"},{"key":"2234_CR2","doi-asserted-by":"publisher","first-page":"769309","DOI":"10.3389\/fendo.2021.769309","volume":"12","author":"M Afzal","year":"2021","unstructured":"Afzal M, Siddiqi N, Ahmad B, Afsheen N, Aslam F, Ali A, et al. Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta-analysis. Front Endocrinol. 2021;12:769309. https:\/\/doi.org\/10.3389\/fendo.2021.769309.","journal-title":"Front Endocrinol"},{"key":"2234_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/07853890.2012.687835","volume":"45","author":"CV Calkin","year":"2013","unstructured":"Calkin CV, Gardner DM, Ransom T, Alda M. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann Med. 2013;45:171\u201381. https:\/\/doi.org\/10.3109\/07853890.2012.687835.","journal-title":"Ann Med"},{"key":"2234_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/bjp.bp.114.152850","volume":"206","author":"CV Calkin","year":"2015","unstructured":"Calkin CV, Ruzickova M, Uher R, Hajek T, Slaney CM, Garnham JS, et al. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry. 2015;206:52\u201357. https:\/\/doi.org\/10.1192\/bjp.bp.114.152850.","journal-title":"Br J Psychiatry"},{"key":"2234_CR5","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1001\/archinternmed.2010.356","volume":"170","author":"A Pan","year":"2010","unstructured":"Pan A, Lucas M, Sun Q, Van Dam RM, Franco OH, Manson JE, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010;170:1884\u201391. https:\/\/doi.org\/10.1001\/archinternmed.2010.356.","journal-title":"Arch Intern Med"},{"key":"2234_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jpsychores.2015.02.010","volume":"78","author":"B Silarova","year":"2015","unstructured":"Silarova B, Giltay EJ, Dortland AVR, Van Rossum EFC, Hoencamp E, Penninx BWJH, et al. Metabolic syndrome in patients with bipolar disorder: comparison with major depressive disorder and non-psychiatric controls. J Psychosom Res. 2015;78:391\u20138. https:\/\/doi.org\/10.1016\/j.jpsychores.2015.02.010.","journal-title":"J Psychosom Res"},{"key":"2234_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1176\/ajp.156.9.1417","volume":"156","author":"F Cassidy","year":"1999","unstructured":"Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417\u201320. https:\/\/doi.org\/10.1176\/ajp.156.9.1417.","journal-title":"Am J Psychiatry"},{"key":"2234_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1176\/appi.ajp.160.1.112","volume":"160","author":"A Fagiolini","year":"2003","unstructured":"Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160:112\u20137. https:\/\/doi.org\/10.1176\/appi.ajp.160.1.112.","journal-title":"Am J Psychiatry"},{"key":"2234_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4088\/jcp.v65n0409","volume":"65","author":"A Fagiolini","year":"2004","unstructured":"Fagiolini A, Kupfer DJ, Rucci P, Scott JA, Novick DM, Frank E. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry. 2004;65:509\u201314. https:\/\/doi.org\/10.4088\/jcp.v65n0409.","journal-title":"J Clin Psychiatry"},{"key":"2234_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1399-5618.2005.00207.x","volume":"7","author":"A Fagiolini","year":"2005","unstructured":"Fagiolini A, Kupfer DJ, Masalehdan A, Scott JA, Houck PR, Frank E. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord. 2005;7:281\u20135. https:\/\/doi.org\/10.1111\/j.1399-5618.2005.00207.x.","journal-title":"Bipolar Disord"},{"key":"2234_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jad.2020.01.145","volume":"266","author":"V Salvi","year":"2020","unstructured":"Salvi V, Di Salvo G, Kor\u010d\u00e1kov\u00e1 J, Torriero S, Aragno E, Koleni\u010d M, et al. Insulin resistance is associated with verbal memory impairment in bipolar disorders. J Affect Disord. 2020;266:610\u20134. https:\/\/doi.org\/10.1016\/j.jad.2020.01.145.","journal-title":"J Affect Disord"},{"key":"2234_CR12","doi-asserted-by":"publisher","first-page":"e924","DOI":"10.4088\/JCP.16m10968","volume":"78","author":"E Mora","year":"2017","unstructured":"Mora E, Portella MJ, Martinez-Alonso M, Teres M, Forcada I, Vieta E, et al. The impact of obesity on cognitive functioning in euthymic bipolar patients: a cross-sectional and longitudinal study. J Clin Psychiatry. 2017;78:e924\u2013e932. https:\/\/doi.org\/10.4088\/JCP.16m10968.","journal-title":"J Clin Psychiatry"},{"key":"2234_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1399-5618.2010.00823.x","volume":"12","author":"DE Kemp","year":"2010","unstructured":"Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine\/metabolic system and treatment outcome. Bipolar Disord. 2010;12:404\u201313. https:\/\/doi.org\/10.1111\/j.1399-5618.2010.00823.x.","journal-title":"Bipolar Disord"},{"key":"2234_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/070674370104600308","volume":"46","author":"RS McIntyre","year":"2001","unstructured":"McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46:273\u201381. https:\/\/doi.org\/10.1177\/070674370104600308.","journal-title":"Can J Psychiatry"},{"key":"2234_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10578-022-01424-6","volume":"27","author":"H Newall","year":"2012","unstructured":"Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol. 2012;27:69\u201375. https:\/\/doi.org\/10.1007\/s10578-022-01424-6.","journal-title":"Int Clin Psychopharmacol"},{"key":"2234_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","volume":"93","author":"T Baptista","year":"2007","unstructured":"Baptista T, Rangel N, Fern\u00e1ndez V, Carrizo E, El Fakih Y, Uzc\u00e1teguiet E, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res. 2007;93:99\u2013108. https:\/\/doi.org\/10.1016\/j.schres.2007.03.029.","journal-title":"Schizophr Res"},{"key":"2234_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.9758\/cpn.2016.14.1.101","volume":"14","author":"SK Praharaj","year":"2016","unstructured":"Praharaj SK. Metformin for lithium-induced weight gain: a case report. Clin Psychopharmacol Neurosci. 2016;14:101\u20133. https:\/\/doi.org\/10.9758\/cpn.2016.14.1.101.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2234_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/JCP.0000000000000392","volume":"35","author":"W Zheng","year":"2015","unstructured":"Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2015;35:499\u2013509. https:\/\/doi.org\/10.1097\/JCP.0000000000000392.","journal-title":"J Clin Psychopharmacol"},{"key":"2234_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1055\/s-0042-120120","volume":"50","author":"R Colle","year":"2017","unstructured":"Colle R, De Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, et al. PPAR-\u03b3 agonists for the treatment of major depression: a review. Pharmacopsychiatry. 2017;50:49\u201355. https:\/\/doi.org\/10.1055\/s-0042-120120.","journal-title":"Pharmacopsychiatry"},{"key":"2234_CR20","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2741\/2802","volume":"13","author":"R Kapadia","year":"2008","unstructured":"Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci J Virtual Libr. 2008;13:1813 https:\/\/doi.org\/10.2741\/2802.","journal-title":"Front Biosci J Virtual Libr"},{"key":"2234_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ejmech.2016.12.020","volume":"126","author":"S Yasmin","year":"2017","unstructured":"Yasmin S, Jayaprakash V. Thiazolidinediones and PPAR orchestra as antidiabetic agents: from past to present. Eur J Med Chem. 2017;126:879\u201393. https:\/\/doi.org\/10.1016\/j.ejmech.2016.12.020.","journal-title":"Eur J Med Chem"},{"key":"2234_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1100\/tsw.2010.32","volume":"10","author":"NL Rasgon","year":"2010","unstructured":"Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. ScientificWorldJournal 2010;10:321\u20138. https:\/\/doi.org\/10.1100\/tsw.2010.32.","journal-title":"ScientificWorldJournal"},{"key":"2234_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/da.22340","volume":"32","author":"A Zeinoddini","year":"2015","unstructured":"Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, et al. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double\u2010blind, placebo\u2010controlled trial. Depress Anxiety. 2015;32:167\u201373. https:\/\/doi.org\/10.1002\/da.22340.","journal-title":"Depress Anxiety"},{"key":"2234_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/life11080819","volume":"11","author":"BDM Jones","year":"2021","unstructured":"Jones BDM, Farooqui S, Kloiber S, Husain MO, Mulsant BH, Husain MI. Targeting metabolic dysfunction for the treatment of mood disorders: review of the evidence. Life Basel Switz. 2021;11:819 https:\/\/doi.org\/10.3390\/life11080819.","journal-title":"Life Basel Switz"},{"key":"2234_CR25","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s13311-020-00878-7","volume":"17","author":"MS Abdallah","year":"2020","unstructured":"Abdallah MS, Mosalam EM, Zidan AAA, Elattar KS, Zaki SA, Ramadan AN, et al. The antidiabetic metformin as an adjunct to antidepressants in patients with major depressive disorder: a proof-of-concept, randomized, double-blind, placebo-controlled trial. Neurotherapeutics. 2020;17:1897\u2013906. https:\/\/doi.org\/10.1007\/s13311-020-00878-7.","journal-title":"Neurotherapeutics"},{"key":"2234_CR26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jad.2018.11.090","volume":"245","author":"A Aftab","year":"2019","unstructured":"Aftab A, Kemp DE, Ganocy SJ, Schinagle M, Conroy C, Brownrigg B, et al. Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. J Affect Disord. 2019;245:957\u201364. https:\/\/doi.org\/10.1016\/j.jad.2018.11.090.","journal-title":"J Affect Disord"},{"key":"2234_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2147\/PPA.S244273","volume":"14","author":"F AlHussain","year":"2020","unstructured":"AlHussain F, AlRuthia Y, Al-Mandeel H, Bellahwal A, Alharbi F, Almogbel Y, et al. Metformin improves the depression symptoms of women with polycystic ovary syndrome in a lifestyle modification program. Patient Prefer Adherence. 2020;14:737\u201346. https:\/\/doi.org\/10.2147\/PPA.S244273.","journal-title":"Patient Prefer Adherence"},{"key":"2234_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/09513590.2018.1498476","volume":"35","author":"H Erensoy","year":"2019","unstructured":"Erensoy H, Niafar M, Ghafarzadeh S, Aghamohammadzadeh N, Nader ND. A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome. Gynecol Endocrinol J Int Soc Gynecol Endocrinol. 2019;35:72\u201375. https:\/\/doi.org\/10.1080\/09513590.2018.1498476.","journal-title":"Gynecol Endocrinol J Int Soc Gynecol Endocrinol"},{"key":"2234_CR29","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/1440-1681.12265","volume":"41","author":"M Guo","year":"2014","unstructured":"Guo M, Mi J, Jiang QM, Xu JM, Tang YY, Tian G, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharm Physiol. 2014;41:650\u20136. https:\/\/doi.org\/10.1111\/1440-1681.12265.","journal-title":"Clin Exp Pharm Physiol"},{"key":"2234_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3892\/etm.2015.2593","volume":"10","author":"Y Hu","year":"2015","unstructured":"Hu Y, Xing H, Dong X, Lu W, Xiao X, Gao L, et al. Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus. Exp Ther Med. 2015;10:1109\u201314. https:\/\/doi.org\/10.3892\/etm.2015.2593.","journal-title":"Exp Ther Med"},{"key":"2234_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.psyneuen.2012.08.010","volume":"38","author":"L Kashani","year":"2013","unstructured":"Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzaeh F, Tehraninejad ES, et al. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 2013;38:767\u201376. https:\/\/doi.org\/10.1016\/j.psyneuen.2012.08.010.","journal-title":"Psychoneuroendocrinology"},{"key":"2234_CR32","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jad.2011.06.033","volume":"136","author":"DE Kemp","year":"2012","unstructured":"Kemp DE, Ismail-Beigi F, Ganocy SJ, Conroy C, Gao K, Obral S, et al. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord. 2012;136:1164\u201373. https:\/\/doi.org\/10.1016\/j.jad.2011.06.033.","journal-title":"J Affect Disord"},{"key":"2234_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40263-014-0158-2","volume":"28","author":"DE Kemp","year":"2014","unstructured":"Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, et al. PPAR-\u03b3 agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs. 2014;28:571\u201381. https:\/\/doi.org\/10.1007\/s40263-014-0158-2.","journal-title":"CNS Drugs"},{"key":"2234_CR34","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.psychres.2015.10.013","volume":"230","author":"KW Lin","year":"2015","unstructured":"Lin KW, Wroolie TE, Robakis T, Rasgon NL. Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response. Psychiatry Res. 2015;230:846\u201352. https:\/\/doi.org\/10.1016\/j.psychres.2015.10.013.","journal-title":"Psychiatry Res"},{"key":"2234_CR35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/PSY.0000000000000985","volume":"83","author":"CD Moulton","year":"2021","unstructured":"Moulton CD, Rokakis AS, Pickup JC, Young AH, Stahl D, Ismail K. SITAgliptin for depressive symptoms in type 2 diabetes: a feasibility randomized controlled trial. Psychosom Med. 2021;83:913\u201323. https:\/\/doi.org\/10.1097\/PSY.0000000000000985.","journal-title":"Psychosom Med"},{"key":"2234_CR36","doi-asserted-by":"publisher","first-page":"697617","DOI":"10.1155\/2014\/697617","volume":"2014","author":"H Roohafza","year":"2014","unstructured":"Roohafza H, Shokouh P, Sadeghi M, Alikhassy Z, Sarrafzadegan N. A possible role for pioglitazone in the management of depressive symptoms in metabolic syndrome patients (EPICAMP Study): a double blind, randomized clinical trial. Int Sch Res Not 2014;2014:697617 https:\/\/doi.org\/10.1155\/2014\/697617.","journal-title":"Int Sch Res Not"},{"key":"2234_CR37","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/npp.2012.58","volume":"37","author":"K Sepanjnia","year":"2012","unstructured":"Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 2012;37:2093\u20132100. https:\/\/doi.org\/10.1038\/npp.2012.58.","journal-title":"Neuropsychopharmacology"},{"key":"2234_CR38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","volume":"207","author":"RB Mansur","year":"2017","unstructured":"Mansur RB, Ahmed J, Cha DS, Woldeyoannes HO, Subramaniapillai M, Lovshin J, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord. 2017;207:114\u201320. https:\/\/doi.org\/10.1016\/j.jad.2016.09.056.","journal-title":"J Affect Disord"},{"key":"2234_CR39","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.euroneuro.2017.08.433","volume":"27","author":"RB Mansur","year":"2017","unstructured":"Mansur RB, Zugman A, Ahmed J, Cha DS, Subramaniapillai M, Lee Y, et al. Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2017;27:1153\u201362. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.08.433.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"2234_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-10-43","volume":"10","author":"S Najjar","year":"2013","unstructured":"Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. J Neuroinflammation. 2013;10:816 https:\/\/doi.org\/10.1186\/1742-2094-10-43.","journal-title":"J Neuroinflammation"},{"key":"2234_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/ejn.14720","volume":"53","author":"R Troubat","year":"2021","unstructured":"Troubat R, Barone P, Leman S, Desmidt T, Cressant A, Atanasova B, et al. Neuroinflammation and depression: a review. Eur J Neurosci. 2021;53:151\u201371. https:\/\/doi.org\/10.1111\/ejn.14720.","journal-title":"Eur J Neurosci"},{"key":"2234_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrn2297","volume":"9","author":"R Dantzer","year":"2008","unstructured":"Dantzer R, O\u2019connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46\u201356. https:\/\/doi.org\/10.1038\/nrn2297.","journal-title":"Nat Rev Neurosci"},{"key":"2234_CR43","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2174\/0929867321666140303143455","volume":"13","author":"B Garc\u00eda-Bueno","year":"2010","unstructured":"Garc\u00eda-Bueno B, P\u00e9rez-Nievas BG, Leza JC. Is there a role for the nuclear receptor PPAR\u03b3 in neuropsychiatric diseases? Int J Neuropsychopharmacol. 2010;13:1411\u201329. https:\/\/doi.org\/10.2174\/0929867321666140303143455.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2234_CR44","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jcmg.2011.08.007","volume":"4","author":"M Mizoguchi","year":"2011","unstructured":"Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET\/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging. 2011;4:1110\u20138. https:\/\/doi.org\/10.1016\/j.jcmg.2011.08.007.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2234_CR45","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/193229681100500233","volume":"5","author":"T Sch\u00f6ndorf","year":"2011","unstructured":"Sch\u00f6ndorf T, Musholt PB, Hohberg C, Forst T, Lehmann U, Fuchs W, et al. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. J Diabetes Sci Technol. 2011;5:426\u201332. https:\/\/doi.org\/10.1177\/193229681100500233.","journal-title":"J Diabetes Sci Technol"},{"key":"2234_CR46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashzaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharm. 2013;715:246\u201355. https:\/\/doi.org\/10.1016\/j.ejphar.2013.05.014.","journal-title":"Eur J Pharm"},{"key":"2234_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.surg.2008.08.038","volume":"145","author":"RW O\u2019Rourke","year":"2009","unstructured":"O\u2019Rourke RW. Inflammation in obesity-related diseases. Surgery. 2009;145:255\u20139. https:\/\/doi.org\/10.1016\/j.surg.2008.08.038.","journal-title":"Surgery"},{"key":"2234_CR48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/mp.2015.22","volume":"21","author":"MH Rapaport","year":"2016","unstructured":"Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 2016;21:71\u20139. https:\/\/doi.org\/10.1038\/mp.2015.22.","journal-title":"Mol Psychiatry"},{"key":"2234_CR49","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1001\/jamapsychiatry.2019.0779","volume":"76","author":"RS McIntyre","year":"2019","unstructured":"McIntyre RS, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I\/II depression: a randomized clinical trial. JAMA Psychiatry. 2019;76:783\u201390. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0779.","journal-title":"JAMA Psychiatry"},{"key":"2234_CR50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.amepre.2008.11.020","volume":"36","author":"DB Allison","year":"2009","unstructured":"Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 2009;36:341\u201350. https:\/\/doi.org\/10.1016\/j.amepre.2008.11.020.","journal-title":"Am J Prev Med"},{"key":"2234_CR51","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1111\/j.1467-789X.2010.00843.x","volume":"12","author":"MS Faith","year":"2011","unstructured":"Faith MS, Butryn M, Wadden TA, Fabricatore A, Nguyen AM, Heymsfield SB. Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev J Int Assoc Study Obes. 2011;12:e438\u2013453. https:\/\/doi.org\/10.1111\/j.1467-789X.2010.00843.x.","journal-title":"Obes Rev J Int Assoc Study Obes"},{"key":"2234_CR52","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1177\/070674370605100502","volume":"51","author":"RS McIntyre","year":"2006","unstructured":"McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry Rev Can Psychiatr. 2006;51:274\u201380. https:\/\/doi.org\/10.1177\/070674370605100502.","journal-title":"Can J Psychiatry Rev Can Psychiatr"},{"key":"2234_CR53","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/sj.ijo.802225","volume":"27","author":"MF Elias","year":"2003","unstructured":"Elias MF, Elias PK, Sullivan LM, Wolf PA, D\u2019Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord J Int Assoc Study Obes. 2003;27:260\u20138. https:\/\/doi.org\/10.1038\/sj.ijo.802225.","journal-title":"Int J Obes Relat Metab Disord J Int Assoc Study Obes"},{"key":"2234_CR54","doi-asserted-by":"publisher","unstructured":"McWhinney SR, Brosch K, Calhoun VD, Crespo- Facorro B, Crossley NA, Dannlowski U, et al. Obesity and brain structure in schizophrenia\u2014ENIGMA study in 3021 individuals. Mol Psychiatry. 2022. https:\/\/doi.org\/10.1038\/s41380-022-01616-5.","DOI":"10.1038\/s41380-022-01616-5"},{"key":"2234_CR55","doi-asserted-by":"publisher","unstructured":"McWhinney SR, Ab\u00e9 C, Alda M, Benedetti F, B\u00f8en E, Del Mar Bonnin C, et al. Diagnosis of bipolar disorders and body mass index predict clustering based on similarities in cortical thickness-ENIGMA study in 2436 individuals. Bipolar Disord. 2021. https:\/\/doi.org\/10.1111\/bdi.13172.","DOI":"10.1111\/bdi.13172"},{"key":"2234_CR56","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/schbul\/sbab064","volume":"47","author":"S McWhinney","year":"2021","unstructured":"McWhinney S, Kolenic M, Franke K, Fialova M, Knytl P, Matejka M, et al. Obesity as a risk factor for accelerated brain ageing in first-episode psychosis\u2014a longitudinal study. Schizophr Bull. 2021;47:1772\u201381. https:\/\/doi.org\/10.1093\/schbul\/sbab064.","journal-title":"Schizophr Bull"},{"key":"2234_CR57","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.1038\/s41380-021-01098-x","volume":"26","author":"SR McWhinney","year":"2021","unstructured":"McWhinney SR, Ab\u00e9 C, Alda M, Benedetti F, B\u00f8en E, Del Mar Bonnin C, et al. Association between body mass index and subcortical brain volumes in bipolar disorders-ENIGMA study in 2735 individuals. Mol Psychiatry. 2021;26:6806\u201319. https:\/\/doi.org\/10.1038\/s41380-021-01098-x.","journal-title":"Mol Psychiatry"},{"key":"2234_CR58","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.neubiorev.2019.11.025","volume":"108","author":"MHC Nota","year":"2020","unstructured":"Nota MHC, Vreeken D, Wiesmann M, Aarts EO, Hazebroek EJ, Kiliaan AJ. Obesity affects brain structure and function- rescue by bariatric surgery. Neurosci Biobehav Rev. 2020;108:646\u201357. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.11.025.","journal-title":"Neurosci Biobehav Rev"},{"key":"2234_CR59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.neubiorev.2016.11.017","volume":"72","author":"N Veronese","year":"2017","unstructured":"Veronese N, Facchini S, Stubbs B, Luchini C, Solmi M, Manzato E, et al. Weight loss is associated with improvements in cognitive function among overweight and obese people: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2017;72:87\u201394. https:\/\/doi.org\/10.1016\/j.neubiorev.2016.11.017.","journal-title":"Neurosci Biobehav Rev"},{"key":"2234_CR60","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jama.2019.0557","volume":"321","author":"J Ma","year":"2019","unstructured":"Ma J, Rosas LG, Lv N, Xiao L, Snowden MB, Venditti EM, et al. Effect of integrated behavioral weight loss treatment and problem-solving therapy on body mass index and depressive symptoms among patients with obesity and depression: the RAINBOW randomized clinical trial. JAMA. 2019;321:869\u201379. https:\/\/doi.org\/10.1001\/jama.2019.0557.","journal-title":"JAMA"},{"key":"2234_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/070674370104600308","volume":"46","author":"RS McIntyre","year":"2001","unstructured":"McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry Rev Can Psychiatr. 2001;46:273\u201381. https:\/\/doi.org\/10.1177\/070674370104600308.","journal-title":"Can J Psychiatry Rev Can Psychiatr"},{"key":"2234_CR62","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1399-5618.2008.00587.x","volume":"10","author":"T Hajek","year":"2008","unstructured":"Hajek T, Hahn M, Slaney C, Garnham J, Green J, R\u016fzickov\u00e1 M, et al. Rapid cycling bipolar disorders in primary and tertiary care treated patients. Bipolar Disord. 2008;10:495\u2013502. https:\/\/doi.org\/10.1111\/j.1399-5618.2008.00587.x.","journal-title":"Bipolar Disord"},{"key":"2234_CR63","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/070674370304800705","volume":"48","author":"M Ruzickova","year":"2003","unstructured":"Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry Rev Can Psychiatr. 2003;48:458\u201361. https:\/\/doi.org\/10.1177\/070674370304800705.","journal-title":"Can J Psychiatry Rev Can Psychiatr"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02234-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02234-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02234-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T12:16:34Z","timestamp":1667909794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02234-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-02234-z","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"11 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"469"}}